Asahi Kasei wins FDA approval for Hovilpri HSV tablets in immunocompromised adults

• Asahi Kasei Therapeutics secured FDA clearance for HOVILPRI (pritelivir) tablets to treat refractory mucocutaneous HSV lesions in immunocompromised adults.
• Label covers lesions unresponsive to acyclovir-class antivirals, with or without documented resistance, offering an oral alternative to IV options.
• Approval relied on Phase 3 PRIOH-1 data showing 63% complete lesion healing by day 28 versus 34% with investigator’s choice.
• Product launch is expected in the US before end-2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Asahi Kasei Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202610091841BIZWIRE_USPR_____20261009_BW917279) on October 09, 2026, and is solely responsible for the information contained therein.